Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, Lee S, Lee E, Taylor K, Cochrane T, Wallington-Gates C, Kwok F, Weber N, Kerridge I, Weston H, Ho PJ, Leahy MF, Horvath N, Spencer A.
Mollee P, et al. Among authors: leahy mf.
Blood Adv. 2024 Jul 23;8(14):3721-3730. doi: 10.1182/bloodadvances.2023012539.
Blood Adv. 2024.
PMID: 38739707
Free PMC article.
Clinical Trial.